Actively Recruiting
Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease
Led by China National Center for Cardiovascular Diseases · Updated on 2025-09-08
240
Participants Needed
2
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.
CONDITIONS
Official Title
Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of chronic coronary artery disease stable for at least 3 months, including history of myocardial infarction, prior coronary intervention, or symptoms with objective evidence of ischemia or significant coronary artery stenosis
- High-sensitivity C-reactive protein (hsCRP) level of 2 mg/L or higher
- Currently taking moderate or higher intensity statin lipid-lowering drugs
- Currently taking antiplatelet drugs
- Signed informed consent
You will not qualify if you...
- Acute coronary syndrome or percutaneous coronary intervention within past 3 months
- Previous coronary artery bypass grafting
- Stroke within past 3 months
- Symptomatic heart failure or left ventricular ejection fraction below 35%
- Planned revascularization or surgery within next 3 months
- Progressive neuromuscular disease or creatine kinase levels over 3 times normal
- Lupus, inflammatory bowel disease, severe arthritis, or other inflammatory diseases
- Current or planned use of immunosuppressants or systemic steroids
- History of hereditary dyslipidemia such as familial hypercholesterolemia
- Change in lipid treatment within past month or planned adjustment
- History of symptomatic non-traumatic cerebral hemorrhage
- Gastrointestinal bleeding or major surgery within past 6 months
- Use of Xuesaitong or similar preparations within past month
- Known adverse reactions to Xuesaitong components
- Active liver disease or elevated liver enzymes above 3 times normal
- Chronic kidney disease or low estimated glomerular filtration rate below 60 ml/min/1.73m2
- Pregnancy, planned pregnancy, or breastfeeding
- Malignant tumors or serious diseases with less than 1 year expected survival
- Mental or communication disorders or cognitive impairment affecting participation
- Participation in other clinical trials within past month
- Known poor adherence to follow-up or medication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100087
Actively Recruiting
2
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Not Yet Recruiting
Research Team
J
Jing Li, MD, PhD
CONTACT
Y
Yan Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here